652 results on '"Kulka, Janina"'
Search Results
202. Sentinel lymph node biopsy and non-sentinel node involvement in special type breast carcinomas with a good prognosis
- Author
-
Cserni, Gábor, primary, Bianchi, Simonetta, additional, Vezzosi, Vania, additional, Arisio, Riccardo, additional, Bori, Rita, additional, Peterse, Johannes L., additional, Sapino, Anna, additional, Drijkoningen, Maria, additional, Kulka, Janina, additional, Eusebi, Vincenzo, additional, Foschini, Maria Pia, additional, Bellocq, Jean-Pierre, additional, Marin, Cristi, additional, Thorstenson, Sten, additional, Amendoeira, Isabel, additional, Reiner-Concin, Angelika, additional, and Decker, Thomas, additional
- Published
- 2007
- Full Text
- View/download PDF
203. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
- Author
-
Kajáry, Kornélia, Tokés, Tímea, Dank, Magdolna, Kulka, Janina, Szakáll Jr., Szabolcs, and Lengyel, Zsolt
- Published
- 2015
- Full Text
- View/download PDF
204. The Distribution of Tight Junctions and Junctional Proteins in the Human Body.
- Author
-
Tokes, Anna-Maria, Schaff, Zsuzsa, Szasz, Attila Marcell, and Kulka, Janina
- Published
- 2013
- Full Text
- View/download PDF
205. The expression of five different claudins in invasive breast carcinomas: Comparison of pT1pN1 and pT1pN0 tumors
- Author
-
To˝kés, Anna-Mária, primary, Kulka, Janina, additional, Paku, Sándor, additional, Máthé, Miklós, additional, Páska, Csilla, additional, Lódi, Csaba, additional, Kiss, András, additional, and Schaff, Zsuzsa, additional
- Published
- 2005
- Full Text
- View/download PDF
206. Human Pathology
- Author
-
Kulka, Janina, primary and Tökés, Anna-Maria, additional
- Published
- 2005
- Full Text
- View/download PDF
207. Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study
- Author
-
Tőkés, Anna-Mária, primary, Kulka, Janina, additional, Paku, Sándor, additional, Szik, Ágnes, additional, Páska, Csilla, additional, Novák, Pál Kaposi, additional, Szilák, László, additional, Kiss, András, additional, Bögi, Krisztina, additional, and Schaff, Zsuzsa, additional
- Published
- 2005
- Full Text
- View/download PDF
208. Extracellular matrix components in breast carcinomas
- Author
-
Kadar, Anna, primary, Tõkés, Anna-Mária, additional, Kulka, Janina, additional, and Robert, Ladislas, additional
- Published
- 2002
- Full Text
- View/download PDF
209. In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement.
- Author
-
Illyes, Ildiko, Tokes, Anna-Maria, Kovacs, Attila, Szasz, A., Molnar, Bela, Molnar, Istvan, Kaszas, Ilona, Baranyak, Zsuzsanna, Laszlo, Zsolt, Kenessey, Istvan, and Kulka, Janina
- Abstract
The aim of the study was to correlate various primary tumor characteristics with lymph node status, to examine sentinel lymph node (SLN) metastasis size and non-SLN axillary involvement, to look for a cut-off size/number value possibly predicting additional axillary involvement with more accuracy and to examine the relationship of SLN metastasis size to overall survival. Of 301 patients who underwent SLN biopsy, 75 had positive SLNs. The size of the metastases was measured. For different size categories, association with the prevalence of non-SLN metastases was assessed. Associations between metastasis size and tumor characteristics and overall survival (OS) were studied. The prevalence of axillary lymph node (ALN) involvement was not significantly different between cases with micrometastasis or macrometastasis in SLNs ( p = 0.124). However, for metastases larger than 6, 7, and 8 mm, the prevalence of ALN involvement was significantly higher ( p = 0.046, 0.022, and 0.025). OS was significantly lower in SLN-positive than in SLN-negative cases ( p = 0.0375). Primary tumor size larger than 20 mm was associated with a significantly higher incidence of SLN metastasis ( p < 0.001), and primary tumor size over 26 mm was associated with additional positive non-SLN ( p < 0.001). Higher mitotic index (≥7) in primary tumors was significantly ( p < 0.001) associated with ALN involvement in SLN-positive cases, whereas higher Ki67 labeling index was not significantly correlated with SLN or ALN involvement. Lymphovascular invasion (LVI) in primary tumors was significantly correlated with SLN positivity ( p < 0.001) but not with further ALN involvement or OS. Tumor size and LVI are predictive for SLN metastasis. Mitotic index, primary tumor size, and larger volume SLN involvement are determinants of further ALN involvement. SLN metastasis size over 6 mm is a strong predictor of further axillary involvement. OS is shorter in the presence of positive SLN. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
210. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.
- Author
-
Cserni, Gábor, Vörös, András, Liepniece-Karele, Inta, Bianchi, Simonetta, Vezzosi, Vania, Grabau, Dorthe, Sapino, Anna, Castellano, Isabella, Regitnig, Peter, Foschini, Maria Pia, Zolota, Vassiliki, Varga, Zsuzsanna, Figueiredo, Paulo, Decker, Thomas, Focke, Cornelia, Kulka, Janina, Kaya, Handan, Reiner-Concin, Angelika, Amendoeira, Isabel, and Callagy, Grace
- Subjects
BREAST cancer ,CANCER cell proliferation ,ESTROGEN receptors ,MITOSIS ,CELL nuclei ,MEDICAL statistics - Abstract
Abstract: The Ki67 labelling index (LI – proportion of staining cells) is widely used to reflect proliferation in breast carcinomas. Several cut-off values have been suggested to distinguish between tumours with low and high proliferative activity. The aim of the current study was to evaluate the distribution of Ki67 LIs in breast carcinomas diagnosed at different institutions by different pathologists using the method reflecting their daily practice. Pathologists using Ki67 were asked to provide data (including the LI, type of the specimen, receptor status, grade) on 100 consecutively stained cases, as well as details of their evaluation. A full dataset of 1709 carcinomas was collected from 19 departments. The median Ki67 LI was 17% for all tumours and 14% for oestrogen receptor-positive and HER2-negative carcinomas. Tumours with higher mitotic counts were associated with higher Ki67 LIs. Ki67 LIs tended to cluster around values ending with 5 or 0 both in cases where the values were obtained by counting the proportion of stained tumour cell nuclei and those where the values were obtained by estimation. On the basis of the distribution pattern described, some currently used Ki67 LI cut off values are not realistic, and it is proposed to select more realistic values ending with 0 or 5. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
211. FDG-PET-CT in the early response evaluation for primary systemic therapy of breast cancer.
- Author
-
Tőkés, Tímea, Torgyík, László, Kulka, Janina, Borka, Katalin, Szász, Attila, Tóth, Andrea, Harsányi, László, Lengyel, Zsolt, Györke, Tamás, and Dank, Magdolna
- Subjects
BREAST cancer treatment ,CANCER chemotherapy ,THERAPEUTICS ,CLINICAL medicine ,PATHOLOGY - Abstract
Primary systemic therapy (PST) is a standard treatment for patients with locally advanced breast cancer. We report one of our patients to demonstrate the optimal use of FDG-PET-CT in the routine clinical workup during PST, especially when clinicians face contradictory clinical and pathological findings, and to show the advantages of this imaging modality in the decision-making process about the initial treatment choice. By reviewing the literature we would also like to confirm that FDG-PET-CT is highly sensitive in the measurement of the early therapeutic response and the prediction of the complete pathological remission, as early as after the first cycle of chemotherapy is administered. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
212. The influence of expertise of the surgical pathologist to undergrading, upgrading, and understaging of prostate cancer in patients undergoing subsequent radical prostatectomy.
- Author
-
Majoros, Attila, Szász, Attila, Nyirády, Péter, Székely, Eszter, Riesz, Péter, Szendrői, Attila, Keszthelyi, Attila, Kulka, Janina, and Romics, Imre
- Abstract
Purpose: The main objective of this retrospective study was to evaluate the influence of pathological experience in histological examination of prostate cancer (PCa) on preoperative understaging (UNS), undergrading (UNG), and upgrading (UPG). Methods: Histopathological data of prostate biopsy (PB) and radical prostatectomy (RP) specimens of patients undergoing subsequent radical prostatectomy ( n = 430) in our center were compared. Histological diagnoses of PB were provided either by corresponding academic pathology institute (Group 1: 322 patients) or by external (nonacademic) departments which had a lower number (≤100/year) of PCa histopathological evaluations (Group 2 108 patients). The rate of UNG, UPG, and UNS in both groups and also the effects of institutional learning curve were analyzed in terms of grading and staging. Results: Significant difference was detected between Group 1 and Group 2 in average preoperative Gleason score (GS) values and in the rate of well, moderately, and poorly differentiated cancers as well. There was also a significant difference in the rate of UNG (29.1 vs. 56.5 %, p < 0.0001). The mean preoperative and postoperative GS in Group 1 was significantly lower in the first 50 than in the last 50 patients, but the rates of UNG, UPG, and UNS did not differ significantly between the groups. Conclusions: The experience of pathologists has direct influence on grading concordance and on UNG and UPG, between PB and RP specimen; however, it has no significant effect on complete preoperative understaging. The bigger pathological experience improves the sensitivity of the histological diagnostic process. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
213. Tenascin Expression and Angiogenesis in Breast Cancers
- Author
-
Tökés, Anna-Mária, primary, Hortoványi, Eszter, additional, Kulka, Janina, additional, Jäkel, Márta, additional, Kerényi, Tibor, additional, and Kádár, Anna, additional
- Published
- 1999
- Full Text
- View/download PDF
214. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer
- Author
-
Kajáry, Kornélia, Tkés, Tímea, Dank, Magdolna, Kulka, Janina, Szakáll, Szabolcs, and Lengyel, Zsolt
- Abstract
The aim of this study was to observe the relationships between different metabolic parameters and clinicopathological features (CPFs) or immunohistochemically defined biological subtypes (IHC-BS) in breast cancer.
- Published
- 2015
- Full Text
- View/download PDF
215. Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.
- Author
-
Szász, A., Majoros, Attila, Rosen, Philip, Srivastava, Shiv, Dobi, Albert, Szendrői, Attila, Kulka, Janina, and Nyirády, Péter
- Abstract
Purpose: Following patients after prostatectomy can be expensive and stressful, therefore, a novel and reliable approach to improve stratification is needed both at diagnosis of PCa and following its treatment. We evaluate the association of both ERG and claudin-4, claudin-5, and beta-catenin expression in tumor tissues of patients with organ-confined and advanced prostatic adenocarcinomas. Methods: A total of 30 patients were included in the study. Nine men who underwent radical prostatectomy for organ-confined (pT2N0M0) cancer (OCC), 10 patients with clinically advanced cancer (CAC), and 11 controls with benign prostatic hypertrophy (BPH). Using immunohistochemistry applied to tissue microarrays, each group was evaluated for beta-catenin, claudin-4, claudin-5, and ERG expression. Results: The expression of ERG was higher in the CAC group when compared to OCC and BPH ( p = 0.7684, p = 0.0224, respectively). Among these patients, 5 from the CAC (45 %) and 5 from the OCC group (56 %) stained positively for ERG ( p = 1.0). The mean staining score for those with ERG+ advanced cancer was greater than that for the ERG+ organ-confined cancer ( p = 0.0209). ERG staining correlated with Gleason score (Pearson's correlation: 0.498, p = 0.0051), but not with serum PSA level (Pearson's correlation: 0.404, p = 0.1202). When analyzing outcome data, high ERG expressing tumors have shown a significantly worse overall survival ( p = 0.0084). Conclusions: Our results of presence or absence of claudin-4 and claudin-5 and ERG staining intensities suggest their potential as prognostic factors for prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
216. A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.
- Author
-
Szekely, Borbala, Iwamoto, Takayuki, Szasz, A., Qi, Yuan, Matsuoka, Junji, Symmans, W., Tokes, Anna-Maria, Kulka, Janina, Swanton, Charles, and Pusztai, Lajos
- Abstract
The goal of this study was to assess the prognostic value of a 3-gene (TOP2A, FOXM1, and MKI67) proliferation score and use it to risk stratify grade-2, estrogen receptor (ER)-positive breast cancers into low- and high-risk groups. We used 4 different breast cancer gene expression datasets including two cohorts of patients who received no systemic adjuvant therapy (Mainz: n = 206, TRANSBIG: n = 134) and two other cohorts that received adjuvant tamoxifen (JBI: n = 227, MDACC/SET: n = 192). We compared individual and combined expression values of the 3 genes between grade 1, 2, and 3 tumors and plotted distant metastasis-free survival (DMFS) curves by the 3-gene score for grade-2 cancers. We compared the prognostic value of the 3-gene score to the Genomic Grade Index (GGI). The individual and combined expression of TOP2A, FOXM1, and MKI67 were significantly different between the 3 histological grade groups with the highest expression in grade-3 and the lowest in grade-1 cancers. Expression levels were variable in grade-2 cancers. Grade-2 tumors with high expression of the 3 genes (>median) showed significantly worse DMFS in one prognostic and one tamoxifen-treated set and showed a similar but non-significant trend for worse survival in the remaining two datasets. The 3-gene score performed equally well in risk stratification as the GGI. A 3-gene proliferation score shows similar prognostic value as the GGI in ER-positive, grade-2 cancers and may serve as basis for a PCR-based assay that could aid prognostic prediction for clinically intermediate-risk cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
217. MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas.
- Author
-
Tömböl, Zsófia, Éder, Katalin, Kovács, Attila, Szabó, Peter M, Kulka, Janina, Likó, István, Zalatnai, Attila, Rácz, Gergely, Tóth, Miklós, Patócs, Attila, Falus, András, Rácz, Károly, and Igaz, Peter
- Published
- 2010
- Full Text
- View/download PDF
218. Syndecan-4 promotes cytokinesis in a phosphorylation-dependent manner.
- Author
-
Keller-Pinter, Aniko, Bottka, Sandor, Timar, Jozsef, Kulka, Janina, Katona, Robert, Dux, Laszlo, Deak, Ferenc, and Szilak, Laszlo
- Subjects
CYTOKINESIS ,CELLULAR mechanics ,PROTEOGLYCANS ,PHOSPHORYLATION ,CANCER cells - Abstract
During mitosis, cells detach, and the cell–matrix interactions become restricted. At the completion of cytokinesis, the two daughter cells are still connected transiently by an intercellular bridge (ICB), which is subjected to abscission, as the terminal step of cytokinesis. Cell adhesion to the matrix is mediated by syndecan-4 (SDC4) transmembrane heparan sulfate proteoglycan. Our present work demonstrated that SDC4 promotes cytokinesis in a phosphorylation-dependent manner in MCF-7 breast adenocarcinoma cells. The serine179-phosphorylation and the ectodomain shedding of SDC4 changed periodically in a cell cycle-dependent way reaching the maximum at G2/M phases. On the contrary, the phospho-resistant Ser179Ala mutant abrogated the shedding. The phosphorylated full-length and shed remnants enriched along the mitotic spindles, and subsequently in the ICBs, however, proper membrane insertion was necessary for midbody localization. Expression of phosphomimicking Ser179Glu SDC4 resulted in incomplete abscission, whereas expression of the phospho-resistant SDC4 led to giant, multinucleated cells. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
219. Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer.
- Author
-
Kilmartin, Darren, O'Loughlin, Mark, Andreu, Xavier, Bagó-Horváth, Zsuzsanna, Bianchi, Simonetta, Chmielik, Ewa, Cserni, Gábor, Figueiredo, Paulo, Floris, Giuseppe, Foschini, Maria Pia, Kovács, Anikó, Heikkilä, Päivi, Kulka, Janina, Laenkholm, Anne-Vibeke, Liepniece-Karele, Inta, Marchiò, Caterina, Provenzano, Elena, Regitnig, Peter, Reiner, Angelika, and Ryška, Aleš
- Subjects
BREAST tumors - Abstract
Simple Summary: The stromal tumour infiltrating lymphocytes (sTILs) within a tumour are a strong predictor of outcome for patients with triple negative breast cancer (TNBC). However, the assessment of sTILs is subject to variation and needs to be standardized in order for it to be used more widely as a biomarker. The aim of this study was to determine the level of consistency that can be achieved when an internet-based scoring aid is used to assist with evaluation of sTILs. Twenty-three breast pathologists across Europe scored sTILs in 49 cases of TNBC taken from a routine diagnostic practice using this aid. The consistency of scoring sTILs was good. However, variation in the distribution of sTILs within the tumour resulted in discordance between pathologists scoring cases, particularly as it caused variability in the selection of regions of the tumour to score. More rigorous training of pathologists is needed for standardization of sTILs assessment, which may potentially be improved using automated approaches. Stromal tumour infiltrating lymphocytes (sTILs) are a strong prognostic marker in triple negative breast cancer (TNBC). Consistency scoring sTILs is good and was excellent when an internet-based scoring aid developed by the TIL-WG was used to score cases in a reproducibility study. This study aimed to evaluate the reproducibility of sTILs assessment using this scoring aid in cases from routine practice and to explore the potential of the tool to overcome variability in scoring. Twenty-three breast pathologists scored sTILs in digitized slides of 49 TNBC biopsies using the scoring aid. Subsequently, fields of view (FOV) from each case were selected by one pathologist and scored by the group using the tool. Inter-observer agreement was good for absolute sTILs (ICC 0.634, 95% CI 0.539–0.735, p < 0.001) but was poor to fair using binary cutpoints. sTILs heterogeneity was the main contributor to disagreement. When pathologists scored the same FOV from each case, inter-observer agreement was excellent for absolute sTILs (ICC 0.798, 95% CI 0.727–0.864, p < 0.001) and good for the 20% (ICC 0.657, 95% CI 0.561–0.756, p < 0.001) and 40% (ICC 0.644, 95% CI 0.546–0.745, p < 0.001) cutpoints. However, there was a wide range of scores for many cases. Reproducibility scoring sTILs is good when the scoring aid is used. Heterogeneity is the main contributor to variance and will need to be overcome for analytic validity to be achieved. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
220. Digital Whole Slide Image Analysis of Elevated Stromal Content and Extracellular Matrix Protein Expression Predicts Adverse Prognosis in Triple-Negative Breast Cancer.
- Author
-
Karancsi, Zsófia, Gregus, Barbara, Krenács, Tibor, Cserni, Gábor, Nagy, Ágnes, Szőcs-Trinfa, Klementina Fruzsina, Kulka, Janina, and Tőkés, Anna Mária
- Subjects
- *
TRIPLE-negative breast cancer , *EXTRACELLULAR matrix proteins , *BREAST cancer prognosis , *OVERALL survival , *PROGNOSIS - Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis and limited treatment options. This study evaluates the prognostic value of stromal markers in TNBC, focusing on the tumor–stroma ratio (TSR) and overall stroma ratio (OSR) in whole slide images (WSI), as well as the expression of type-I collagen, type-III collagen, and fibrillin-1 on tissue microarrays (TMAs), using both visual assessment and digital image analysis (DIA). A total of 101 female TNBC patients, primarily treated with surgery between 2005 and 2016, were included. We found that high visual OSR correlates with worse overall survival (OS), advanced pN categories, lower stromal tumor-infiltrating lymphocyte count (sTIL), lower mitotic index, and patient age (p < 0.05). TSR showed significant connections to the pN category and mitotic index (p < 0.01). High expression levels of type-I collagen (>45%), type-III collagen (>30%), and fibrillin-1 (>20%) were linked to significantly worse OS (p = 0.004, p = 0.013, and p = 0.005, respectively) and progression-free survival (PFS) (p = 0.028, p = 0.025, and p = 0.002, respectively), validated at the mRNA level. Our results highlight the importance of stromal characteristics in promoting tumor progression and metastasis and that targeting extracellular matrix (ECM) components may offer novel therapeutic strategies. Furthermore, DIA can be more accurate and objective in evaluating TSR, OSR, and immunodetected stromal markers than traditional visual examination. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
221. Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
- Author
-
Ellis, Ian, Webster, Fleur, Allison, Kimberly H, Dang, Chau, Gobbi, Helenice, Kulka, Janina, Lakhani, Sunil R, Moriya, Takuya, Quinn, Cecily M, Sapino, Anna, Schnitt, Stuart, Sibbering, D Mark, Slodkowska, Elzbieta, Yang, Wentao, and Tan, Puay H
- Subjects
- *
CANCER invasiveness , *BREAST cancer , *CANCER patients , *PATHOLOGISTS , *PATHOLOGY , *BREAST - Abstract
Background and Objectives: Current national or regional guidelines for the pathology reporting on invasive breast cancer differ in certain aspects, resulting in divergent reporting practice and a lack of comparability of data. Here we report on a new international dataset for the pathology reporting of resection specimens with invasive cancer of the breast. The dataset was produced under the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter‐)national pathology and cancer organizations. Methods and Results: The established ICCR process for dataset development was followed. An international expert panel consisting of breast pathologists, a surgeon, and an oncologist prepared a draft set of core and noncore data items based on a critical review and discussion of current evidence. Commentary was provided for each data item to explain the rationale for selecting it as a core or noncore element, its clinical relevance, and to highlight potential areas of disagreement or lack of evidence, in which case a consensus position was formulated. Following international public consultation, the document was finalized and ratified, and the dataset, which includes a synoptic reporting guide, was published on the ICCR website. Conclusions: This first international dataset for invasive cancer of the breast is intended to promote high‐quality, standardized pathology reporting. Its widespread adoption will improve consistency of reporting, facilitate multidisciplinary communication, and enhance comparability of data, all of which will help to improve the management of invasive breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
222. Retrospective Analysis of Clinicopathological Characteristics and Family History Data of Early-Onset Breast Cancer: A Single-Institutional Study of Hungarian Patients
- Author
-
Madaras, Lilla, Baranyák, Zsuzsanna, Kulka, Janina, Szász, Attila, Kovács, Attila, Lan, Phan, Székely, Borbála, Dank, Magdolna, Nagy, Tibor, Kiss, Orsolya, Harsányi, László, Barbai, Tamás, Kenessey, István, and Tőkés, Anna
- Abstract
Patients at young age (≤35 years) diagnosed with breast cancer (BC) are considered to have poor prognosis. The aim of the present study was to retrospectively analyse clinicopathological characteristics and prognosis in a group of young BC patients. We included women diagnosed with invasive breast carcinoma younger than/or at the age of 35 years. Between 1999 and 2009, 107 women with early-onset BC were selected from the database of the 2nd Department of Pathology at Semmelweis University. For clinicopathological comparison, 55 women (36–45 years), 214 women (46–65 years), 110 women (66–75 years) and 58 women (76≤ years) were also included in the analysis. Family history, clinicopathological and follow-up data were analysed. The tissue specimens were reviewed for histological type, nuclear grade, and estrogen receptor (ER), progesterone receptor (PgR), Ki67 and HER2 status (IHC4). The mean age in the study group was 31.6 years at the time of diagnosis. Histology showed a high incidence of grade III tumours in this group of patients (67.9 %), while only four cases (3.8 %) were considered grade I. According to the immunohistochemical results, 35.3 % of the study cases were considered as Luminal B (LumB: either being higly proliferative or co-expressing HER2) and 33.3 % as triple negative breast carcinomas (TNBC). The detailed questionnaire related to family history was completed and received in 49/107 cases (45.8 %). Analysis of these data revealed an affected family history of breast or ovarian carcinoma in first and second degree relatives in 51.0 %. A high proportion (52.0 %) of TNBC was observed among young women with a family history of the disease. Survival analysis of the 107 patients showed that 25 (23.3 %) women died until 31 December 2012. No significant difference in survival was detectable considering the regimen of systemic treatment (p= 0.188). Regarding clinicopathological parameters, the immunophenotypes, grade, pT and pN values differred substantially between the age groups (p= 0.001, for all), and the shortest relapse-free survival was seen among the youngest BC patients. This analysis illustrates that breast cancer arising in young women is characterized by the presence of less favorable subtypes such as LumB and TNBC. The increased proportion of TNBC was especially remarquable in the group of patients presenting with family history of the disease. The fact that a high rate of death occured and no significant difference in OS were notable regarding the scheme of systemic therapies (neoadjuvant vs. adjuvant) highlight the necessity of the development of new treatment strategies.
- Published
- 2013
- Full Text
- View/download PDF
223. Expression of Tight Junction Molecules in Breast Carcinomas Analysed by Array PCR and Immunohistochemistry
- Author
-
Tőkés, Anna-Mária, Szász, Attila, Juhász, Éva, Schaff, Zsuzsa, Harsányi, László, Molnár, István, Baranyai, Zsolt, Besznyák, István, Zaránd, Attila, Salamon, Ferenc, and Kulka, Janina
- Abstract
Abstract: In the past few decades an enormous amount of data became known to clarify the molecular composition and architecture of tight junctions (TJs). Despite the efforts, the expression and function of several TJ genes and proteins in breast carcinoma are still not known and some of the data are contradictory. The expression of forty-four TJ associated genes was examined at mRNA level in eighteen invasive ductal breast carcinoma samples and corresponding normal breast tissues by using low density array PCR. Expressions of claudins (CLDNs) 5, 10, 16, 17, and 18, and ZO-1, ZO-2 were evaluated by immunohistochemistry as well. Using immunohistochemical phenotype as a surrogate for the genetic subtype, 11 luminal A, 3 luminal B, 3 triple negative and one HER2+ cases were included. Ten genes were significantly downregulated in tumors compared with normal breast tissues (CLDNs 5, 10, 16, 18, 19, CTNNAL1, JAM-B, ZO-1, ZO-2 and PARD3), whereas one gene (CLDN17) was significantly up-regulated in tumors when compared with normal breast. At protein level CLDNs 5, 10, 16, 18, ZO-1 and ZO-2 were downregulated in tumors as compared with normal breast tissue. CLDN17 showed variable expression in tumor tissues in comparison to normal breast. In the single HER2+ tumor when compared with the other subtypes CLDNs 5, 16, 17, 18, CTNNAL1, JAM-B, ZO-1, ZO-2 and PARD3 genes were found to be upregulated. We found altered TJ genes and proteins whose expression has not yet been associated with breast carcinoma. Our findings show a tendency of TJ genes and proteins to be downregulated in breast cancer. Further studies are necessary to examine whether the downregulation of the above mentioned TJ associated genes and proteins may contribute to the malignant progression of invasive ductal breast carcinomas.
- Published
- 2012
- Full Text
- View/download PDF
224. Estrogen Receptor Negative and Progesterone Receptor Positive Breast Carcinomas—How Frequent are they?
- Author
-
Cserni, Gábor, Francz, Monika, Kálmán, Endre, Kelemen, Gyöngyi, Komjáthy, Detre, Kovács, Ilona, Kulka, Janina, Sarkadi, László, Udvarhelyi, Nóra, Vass, László, and Vörös, András
- Abstract
Abstract: Estrogen receptor (ER) testing has become an important part of breast cancer reporting as the ER status is a predictor of hormonal treatment efficacy. Progesteron receptors (PR) are often tested in parallel, and the best response to hormonal manipulations can be expected in tumors positive for both receptors. The existence of breast cancers with an ER negative and PR positive phenotype is controversial. A series of cases with this phenotype were reevaluated to clarify the existence and the frequency of this entity. A total of 205/6587 (3.1%; range of the rate per department: 0.3–7.1%.) cases reported to have the ER-negative and PR-positive status by immunohistochemistry were collected from 9 Hungarian departments. After careful reevaluation of the tumor slides and control tissues with a 1% cut-off for positivity and restaining of the questionable cases, all but 1 of the reevaluable 182 cases changed their original phenotype. Most cases converted to dual positives (n = 124) or dual negatives (n = 31) or unassessable / questionable. ER-negative and PR-positive breast cancers are very rare if existing. Such a phenotype should prompt reassessment.
- Published
- 2011
- Full Text
- View/download PDF
225. Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era
- Author
-
Montemurro, Filippo, Redana, Stefania, Viale, Giuseppe, Sanna, Giuseppina, Donadio, Michela, Valabrega, Giorgio, del Curto, Barbara, Bottini, Alberto, Botti, Gerardo, Paolo dei Tos, Angelo, Jacomuzzi, Maria Elena, Di Bonito, Maurizio, Danese, Saverio, Clavarezza, Matteo, Kulka, Janina, Di Palma, Silvana, Durando, Antonio, Sapino, Anna, and Aglietta, Massimo
- Abstract
Patients with HER2-positive breast cancer whose disease has become resistant to the anti-HER2 monoclonal antibody trastuzumab can benefit from lapatinib, a dual epidermal growth factor receptor/HER2 tyrosine kinase (TK) inhibitor. Before the availability of this compound, trastuzumab was often continued beyond disease progression, usually in addition to further chemotherapy, an approach which was not based on randomized studies. We sought to retrospectively compare the clinical outcomes of patients who, upon progression during an initial trastuzumab-based regimen, stopped or continued trastuzumab in addition to further chemotherapy.
- Published
- 2008
- Full Text
- View/download PDF
226. Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes.
- Author
-
Szeitz, Beáta, Pipek, Orsolya, Kulka, Janina, Szundi, Csilla, Rusz, Orsolya, Tőkés, Tímea, Szász, Attila Marcell, Kovács, Kristóf Attila, Pesti, Adrián, Ben Arie, Taya Beri, Gángó, Ambrus, Fülöp, Zsolt, Drágus, Emőke, Vári-Kakas, Stefan A., and Tőkés, Anna Mária
- Subjects
- *
BREAST cancer prognosis , *DISEASE progression , *CELL physiology , *GENE expression , *GENES , *IMMUNITY , *CD4 lymphocyte count , *T cells , *BREAST tumors - Abstract
Simple Summary: The tumor immune microenvironment of different breast carcinoma (BC) subtypes and immune gene assembly of metastasizing and non-metastasizing HER2-negative BCs was analyzed. Examination of 309 Hematoxylin and Eosin-stained slides highlighted that the distribution of tumor infiltrating lymphocytes (TILs) from peritumoral, stromal and intratumoral regions varied greatly within all subtypes, with most tumors (66.01%) belonging to the immunologically "cold" group. Hormone receptor (HR) negative subtypes generally showed higher immune activity in all analyzed regions. No survival benefit was detected based on the spatial distribution of TILs. A lower CD4+/CD8+ ratio at the stromal internal tumor region indicated longer distant metastasis-free survival. When assessing immune gene expression between metastatic and non-metastatic BCs, the list of differentially expressed genes were non-identical across luminal and TNBCs, suggesting that these subtypes may use different mechanisms to bypass the immunological surveillance. Understanding these differences in the immune gene assembly may pave the way to the development of new immune-modulation therapies. We hypothesized that different BC subtypes are characterized by spatially distinct tumor immune microenvironment (TIME) and that immune gene assembly of metastatic (Met) and non-metastatic (Ctrl) BCs vary across subtypes. Peritumoral, stromal and intratumoral TIL was assessed on 309 BC cases. Hot, cold and immune-excluded groups were defined, and the prognostic role of this classification was assessed. CD4+/CD8+ positivity was analyzed in 75 cases in four systematically predefined tumor regions. Immune gene expression of Met and Ctrl HER2-negative BCs was compared by using NanoString nCounter technology. The amount of TIL infiltration varied greatly within all BC subtypes. Two-third of the cases were cold tumors with no significant survival difference compared to hot tumors. A lower CD4+/CD8+ ratio at the stromal internal tumor region was significantly associated with longer distant metastasis-free survival. The differentially expressed immune genes between Met and Ctrl varied across the studied BC subtypes with TNBC showing distinct features from the luminal subtypes. The TIME is characterized by a considerable heterogeneity; however, low level of TILs does not equate to disease progression. The differences in immune gene expression observed between Met and Ctrl breast carcinomas call attention to the important role of altered immune function in BC progression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
227. A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
- Author
-
Bossuyt, Veerle, Provenzano, Elena, Symmans, W Fraser, Webster, Fleur, Allison, Kimberly H, Dang, Chau, Gobbi, Helenice, Kulka, Janina, Lakhani, Sunil R, Moriya, Takuya, Quinn, Cecily M, Sapino, Anna, Schnitt, Stuart, Sibbering, D Mark, Slodkowska, Elzbieta, Yang, Wentao, Tan, Puay Hoon, and Ellis, Ian
- Subjects
- *
BREAST , *NEOADJUVANT chemotherapy , *LOBULAR carcinoma , *CARCINOMA in situ , *CARCINOMA , *DUCTAL carcinoma - Abstract
Aims: The International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter‐)national pathology and cancer organisations, is an initiative aimed at providing a unified international approach to reporting cancer. ICCR recently published new data sets for the reporting of invasive breast carcinoma, surgically removed lymph nodes for breast tumours and ductal carcinoma in situ, variants of lobular carcinoma in situ and low‐grade lesions. The data set in this paper addresses the neoadjuvant setting. The aim is to promote high‐quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment that can be used for subsequent management decisions for each patient. Methods: The ICCR convened expert panels of breast pathologists with a representative surgeon and oncologist to critically review and discuss current evidence. Feedback from the international public consultation was critical in the development of this data set. Results: The expert panel concluded that a dedicated data set was required for reporting of breast specimens post‐neoadjuvant therapy with inclusion of data elements specific to the neoadjuvant setting as core or non‐core elements. This data set proposes a practical approach for handling and reporting breast resection specimens following neoadjuvant therapy. The comments for each data element clarify terminology, discuss available evidence and highlight areas with limited evidence that need further study. This data set overlaps with, and should be used in conjunction with, the data sets for the reporting of invasive breast carcinoma and surgically removed lymph nodes from patients with breast tumours, as appropriate. Key issues specific to the neoadjuvant setting are included in this paper. The entire data set is freely available on the ICCR website. Conclusions: High‐quality, standardised reporting of tumour response and residual disease after neoadjuvant treatment are critical for subsequent management decisions for each patient. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
228. Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer
- Author
-
Kilmartin, Darren, O’Loughlin, Mark, Andreu, Xavier, Bagó-Horváth, Zsuzsanna, Bianchi, Simonetta, Chmielik, Ewa, Cserni, Gábor, Figueiredo, Paulo, Floris, Giuseppe, Foschini, Maria Pia, Kovács, Anikó, Heikkilä, Päivi, Kulka, Janina, Laenkholm, Anne-Vibeke, Liepniece-Karele, Inta, Marchiò, Caterina, Provenzano, Elena, Regitnig, Peter, Reiner, Angelika, Ryška, Aleš, Sapino, Anna, Specht Stovgaard, Elisabeth, Quinn, Cecily, Zolota, Vasiliki, Webber, Mark, Roshan, Davood, Glynn, Sharon A., and Callagy, Grace
- Subjects
breast cancer ,international immuno-oncology biomarker working group ,TILs ,sTILs ,reproducibility ,triple negative ,3. Good health - Abstract
Stromal tumour infiltrating lymphocytes (sTILs) are a strong prognostic marker in triple negative breast cancer (TNBC). Consistency scoring sTILs is good and was excellent when an internet-based scoring aid developed by the TIL-WG was used to score cases in a reproducibility study. This study aimed to evaluate the reproducibility of sTILs assessment using this scoring aid in cases from routine practice and to explore the potential of the tool to overcome variability in scoring. Twenty-three breast pathologists scored sTILs in digitized slides of 49 TNBC biopsies using the scoring aid. Subsequently, fields of view (FOV) from each case were selected by one pathologist and scored by the group using the tool. Inter-observer agreement was good for absolute sTILs (ICC 0.634, 95% CI 0.539–0.735, p 0.001) but was poor to fair using binary cutpoints. sTILs heterogeneity was the main contributor to disagreement. When pathologists scored the same FOV from each case, inter-observer agreement was excellent for absolute sTILs (ICC 0.798, 95% CI 0.727–0.864, p 0.001) and good for the 20% (ICC 0.657, 95% CI 0.561–0.756, p 0.001) and 40% (ICC 0.644, 95% CI 0.546–0.745, p 0.001) cutpoints. However, there was a wide range of scores for many cases. Reproducibility scoring sTILs is good when the scoring aid is used. Heterogeneity is the main contributor to variance and will need to be overcome for analytic validity to be achieved.
229. Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series.
- Author
-
Nádorvári, Maja L., Kenessey, István, Kiss, András, Barbai, Tamás, Kulka, Janina, Rásó, Erzsébet, and Tímár, József
- Abstract
Background: The tumor-agnostic indication of immune checkpoint inhibitors to treat cancers with mismatch repair deficiency (dMMR)/microsatellite instability (MSI) increased the demand for such tests beyond Lynch syndrome. International guideline recommendations accept immunohistochemistry (IHC) for dMMR or molecular techniques (PCR or NGS) for MSI status determinations considering the two tests are equal, although there are scattered reports contradicting to this presumption. Materials and methods: Here we have directly compared four protein MMR immunohistochemistry (IHC) to MSI Pentaplex PCR test in a large cancer patient cohort (n = 1306) of our diagnostic center where the two tests have been run parallel in 703 cases. Results: In this study we have found a high discrepancy rate (19.3%) of the two tests which was independent of the tumor types. The MSI PCR sensitivity for MMR IHC status was found to be very low resulting in a relatively low positive and negative predicting values. As a consequence, the correlation of the two tests was low (kappa < 0.7). During analysis of the possible contributing factors of this poor performance, we have excluded low tumor percentage of the samples, but identified dMMR phenotypes (classic versus non-classic or unusual) as possible contributors. Conclusion: Although our cohort did not include samples with identified technical errors, our data strongly support previous reports that unidentified preanalytical factors might have the major influence on the poor performance of the MSI PCR and MMR IHC. Furthermore, the case is open whether the two test types are equally powerful predictive markers of immunotherapies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
230. Evaluation of the routine use of E‐cadherin immunohistochemistry in the typing of breast carcinomas: results of a randomized diagnostic study.
- Author
-
Cserni, Gábor, Kálmán, Endre, Udvarhelyi, Nóra, Papp, Eszter, Grote, Isabel, Bartels, Stephan, Christgen, Matthias, Kreipe, Hans, and Kulka, Janina
- Subjects
- *
BREAST , *CADHERINS , *LOBULAR carcinoma , *IMMUNOHISTOCHEMISTRY , *CARCINOMA , *DIAGNOSTIC imaging - Abstract
Aims: Invasive lobular carcinoma (ILC) has distinct morphology and association with loss of E‐cadherin function. It has special clinical and imaging features, and its proper recognition is important. Following a recent proposal, we tested the value of the routine use of E‐cadherin immunohistochemistry (IHC) in recognizing ILC. Methods and results: Five pathologists with experience in breast pathology from four Hungarian institutions histotyped 1001 breast cancers from diagnostic core biopsies or excision specimens randomly assigned to haematoxylin and eosin (HE) diagnosis first, followed by E‐cadherin IHC; or to immediate HE and E‐cadherin‐based diagnosis. Of 524 cases with HE diagnosis, 73(14%) were deemed uncertain. E‐cadherin made the initial histological type change in 14/524 cases (2.7%), including three with confident HE‐based type allocation. Use of E‐cadherin immunostaining was considered useful in 88/477 cases (18%) with immediate dual assessment, and typing uncertainty went down to 5% (25/477 cases), but was not zero. Collective assessment of 171 uncertain, difficult, nonclassical cases resulted in consensus diagnosis in most cases, but 15 cases were still doubtful as concerns their proper histological type. CDH1 gene sequencing was attempted and successful in 13; pathogenic genetic alterations were identified in seven cases. Conclusions: The routine use of E‐cadherin IHC decreases the uncertainty in typing and improves the typing accuracy at the cost of potentially redundant additional immunostains. Furthermore, this procedure does not exclude uncertainty due to E‐cadherin‐positive ILCs, which are occasionally difficult to confidently label as ILC, especially when the growth pattern is not classic. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
231. Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.
- Author
-
Brown, David, Smeets, Dominiek, Székely, Borbála, Larsimont, Denis, Szász, A. Marcell, Adnet, Pierre-Yves, Rothé, Françoise, Rouas, Ghizlane, Nagy, Zsófia I, Faragó, Zsófia, Tőkés, Anna-Mária, Dank, Magdolna, Szentmártoni, Gyöngyvér, Udvarhelyi, Nóra, Zoppoli, Gabriele, Pusztai, Lajos, Piccart, Martine, Kulka, Janina, Lambrechts, Diether, and Sotiriou, Christos
- Abstract
This corrects the article DOI: 10.1038/ncomms14944 [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
232. Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival.
- Author
-
Szentmártoni, Gyöngyvér, Tőkés, Anna-Mária, Tőkés, Timea, Somlai, Krisztián, Szász, Attila Marcell, Torgyík, László, Kulka, Janina, and Dank, Magdolna
- Published
- 2016
233. The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience.
- Author
-
Dank, Magdolna, Mühl, Dorottya, Pölhös, Annamária, Csanda, Renata, Herold, Magdolna, Kovacs, Attila Kristof, Madaras, Lilla, Kulka, Janina, Palhazy, Timea, Tokes, Anna-Maria, Toth, Monika, Ujhelyi, Mihaly, Szasz, Attila Marcell, and Herold, Zoltan
- Subjects
- *
GENE expression , *CANCER patients , *GENE expression profiling , *HORMONE receptors , *EPIDERMAL growth factor receptors , *BREAST cancer , *BREAST , *FLUORESCENCE in situ hybridization - Abstract
Background: Breast cancer has been categorized into molecular subtypes using immunohistochemical staining (IHC) and fluorescence in situ hybridization (FISH) since the early 2000s. However, recent research suggests that gene expression testing, specifically Prosigna® Prediction Analysis of Microarray 50 (PAM50), provides more accurate classification methods. In this retrospective study, we compared the results of IHC/FISH and PAM50 testing. We also examined the impact of various PAM50 parameters on overall survival (OS) and progression-free survival (PFS). Results: We analyzed 42 unilateral breast cancer samples, with 18 classified as luminal A, 10 as luminal B, 8 as Human epidermal growth factor receptor 2 (HER2)-positive, and 6 as basal-like using PAM50. Interestingly, 17 out of the 42 samples (40.47%) showed discordant results between histopathological assessment and the PAM50 classifier. While routine IHC/FISH resulted in classification differences for a quarter to a third of samples within each subtype, all basal-like tumors were misclassified. Hormone receptor-positive tumors (hazard rate: 8.7803; p = 0.0085) and patients who had higher 10-year recurrence risk scores (hazard rate: 1.0539; p = 0.0201) had shorter OS and PFS. Conclusions: Our study supports the existing understanding of molecular subtypes in breast cancer and emphasizes the overlap between clinical characteristics and molecular subtyping. These findings underscore the value of gene expression profiling, such as PAM50, in improving treatment decisions for breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
234. Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort.
- Author
-
Pipek, Orsolya, Alpár, Donát, Rusz, Orsolya, Bödör, Csaba, Udvarnoki, Zoltán, Medgyes-Horváth, Anna, Csabai, István, Szállási, Zoltán, Madaras, Lilla, Kahán, Zsuzsanna, Cserni, Gábor, Kővári, Bence, Kulka, Janina, and Tőkés, Anna Mária
- Subjects
- *
BREAST , *SOMATIC mutation , *BREAST cancer , *SINGLE nucleotide polymorphisms , *CHECKPOINT kinase 2 , *CANCER patients - Abstract
A limited number of studies have focused on the mutational landscape of breast cancer in different ethnic populations within Europe and compared the data with other ethnic groups and databases. We performed whole-genome sequencing of 63 samples from 29 Hungarian breast cancer patients. We validated a subset of the identified variants at the DNA level using the Illumina TruSight Oncology (TSO) 500 assay. Canonical breast-cancer-associated genes with pathogenic germline mutations were CHEK2 and ATM. Nearly all the observed germline mutations were as frequent in the Hungarian breast cancer cohort as in independent European populations. The majority of the detected somatic short variants were single-nucleotide polymorphisms (SNPs), and only 8% and 6% of them were deletions or insertions, respectively. The genes most frequently affected by somatic mutations were KMT2C (31%), MUC4 (34%), PIK3CA (18%), and TP53 (34%). Copy number alterations were most common in the NBN, RAD51C, BRIP1, and CDH1 genes. For many samples, the somatic mutational landscape was dominated by mutational processes associated with homologous recombination deficiency (HRD). Our study, as the first breast tumor/normal sequencing study in Hungary, revealed several aspects of the significantly mutated genes and mutational signatures, and some of the copy number variations and somatic fusion events. Multiple signs of HRD were detected, highlighting the value of the comprehensive genomic characterization of breast cancer patient populations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
235. ONEST (Observers Needed to Evaluate Subjective Tests) Analysis of Stromal Tumour-Infiltrating Lymphocytes (sTILs) in Breast Cancer and Its Limitations.
- Author
-
Cserni, Bálint, Kilmartin, Darren, O'Loughlin, Mark, Andreu, Xavier, Bagó-Horváth, Zsuzsanna, Bianchi, Simonetta, Chmielik, Ewa, Figueiredo, Paulo, Floris, Giuseppe, Foschini, Maria Pia, Kovács, Anikó, Heikkilä, Päivi, Kulka, Janina, Laenkholm, Anne-Vibeke, Liepniece-Karele, Inta, Marchiò, Caterina, Provenzano, Elena, Regitnig, Peter, Reiner, Angelika, and Ryška, Aleš
- Subjects
- *
COMPUTER software , *LYMPHOCYTES , *GASTROINTESTINAL tumors , *INTER-observer reliability , *HISTOLOGY , *BREAST tumors ,RESEARCH evaluation - Abstract
Simple Summary: Tumour-infiltrating lymphocytes (TILs) reflect the host's response against tumours. TILs have a strong prognostic effect in the so-called triple-negative (oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 negative) subset of breast cancers and predict a better response when primary systemic (neoadjuvant) treatment is administered. Although they are easy to assess, their quantitative assessment is subject to some inter-observer variation. ONEST (Observers Needed to Evaluate Subjective Tests) is a new way of analysing inter-observer variability and helps in estimating the number of observers required for a more reliable estimation of this phenomenon. This aspect of reproducibility for TILs has not been explored previously. Our analysis suggests that between six and nine pathologists can give a good approximation of inter-observer agreement in TIL assessments. Tumour-infiltrating lymphocytes (TILs) reflect antitumour immunity. Their evaluation of histopathology specimens is influenced by several factors and is subject to issues of reproducibility. ONEST (Observers Needed to Evaluate Subjective Tests) helps in determining the number of observers that would be sufficient for the reliable estimation of inter-observer agreement of TIL categorisation. This has not been explored previously in relation to TILs. ONEST analyses, using an open-source software developed by the first author, were performed on TIL quantification in breast cancers taken from two previous studies. These were one reproducibility study involving 49 breast cancers, 23 in the first circulation and 14 pathologists in the second circulation, and one study involving 100 cases and 9 pathologists. In addition to the estimates of the number of observers required, other factors influencing the results of ONEST were examined. The analyses reveal that between six and nine observers (range 2–11) are most commonly needed to give a robust estimate of reproducibility. In addition, the number and experience of observers, the distribution of values around or away from the extremes, and outliers in the classification also influence the results. Due to the simplicity and the potentially relevant information it may give, we propose ONEST to be a part of new reproducibility analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
236. Correspondence.
- Author
-
Kulka, Janina and Tökés, Anna-Maria
- Published
- 2005
- Full Text
- View/download PDF
237. Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer.
- Author
-
Kocsmár, Ildikó, Kocsmár, Éva, Pajor, Gábor, Kulka, Janina, Székely, Eszter, Kristiansen, Glen, Schilling, Oliver, Nyirády, Péter, Kiss, András, Schaff, Zsuzsa, Riesz, Péter, and Lotz, Gábor
- Subjects
- *
DISEASE progression , *CONFIDENCE intervals , *ONCOGENES , *IMMUNOHISTOCHEMISTRY , *RETROSPECTIVE studies , *NON-muscle invasive bladder cancer , *GENE expression , *RISK assessment , *CHROMOSOME abnormalities , *IN situ hybridization , *GENE amplification - Abstract
Simple Summary: The addition of chromosome 17 polysomy/HER2 amplification status to the updated EAU and AUA scores improves their accuracy, allowing molecular reclassification of EAU high-risk NMIBCs and G2 tumors. Based on this, we propose to reclassify the non-HER2 amplified, non-polysomic EAU 3–4 (high- and very high-risk) cases to the EAU 2 (intermediate) risk group to prevent unnecessarily strict follow-up and treatment for these patients. Furthermore, to classify Chr17 polysomic and/or HER2 amplified G2 tumors as high-grade (HG) and non-HER2 amplified, non-polysomic G2 tumors as low-grade (LG) NMIBCs (G1 and G3 tumors remain graded as low- and high-grade, respectively). Thus, the implementation of Chr17 polysomy/HER2 amplification testing would provide an immediate and simple solution to further refine the prognostic risk assessment of NMIBCs in the uro-oncology practice. Progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive disease (MIBC) significantly worsens life expectancy. Its risk can be assessed by clinicopathological factors according to international guidelines. However, additional molecular markers are needed to refine and improve the prediction. Therefore, in the present study, we aimed to predict the progression of NMIBCs to MIBC by assessing p53 expression, polysomy of chromosome 17 (Chr17) and HER2 status in the tissue specimens of the tumors of 90 NMIBC patients. Median follow-up was 77 months (range 2–158). Patients with Chr17 polysomy or HER2 gene amplification had a higher rate of disease progression (hazard ratio: 7.44; p < 0.001 and 4.04; p = 0.033, respectively; univariate Cox regression). Multivariable Cox regression models demonstrated that the addition of either Chr17 polysomy or HER2 gene amplification status to the European Association of Urology (EAU) progression risk score increases the c-index (from 0.741/EAU/ to 0.793 and 0.755, respectively), indicating that Chr17 polysomy/HER2 amplification status information improves the accuracy of the EAU risk table in predicting disease progression. HER2/Chr17 in situ hybridization can be used to select non-progressive cases not requiring strict follow-up, by reclassifying non-HER2-amplified, non-polysomic NMIBCs from the high- and very high-risk groups of EAU to the intermediate-risk group. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
238. Invasive Oncocytic Carcinoma
- Author
-
de Biase, Dario, Ragazzi, Moira, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
239. Invasive Mucinous Carcinoma
- Author
-
DeGaetano, James S., Said Huntingford, Ian, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
240. Invasive Secretory Carcinoma
- Author
-
Sidoni, Angelo, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
241. Invasive Carcinoma NST
- Author
-
Ellis, Ian, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
242. Invasive Lobular Carcinoma
- Author
-
Foschini, Maria P., Morandi, Luca, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
243. Inflammatory Myofibroblastic Tumor of the Breast
- Author
-
Magro, Gaetano, Salvatorelli, Lucia, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
244. Invasive Metaplastic Carcinoma
- Author
-
Marchiò, Caterina, Chartier, Suzanne, Bataillon, Guillaume, Vincent-Salomon, Anne, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
245. Intraductal Papillary Carcinoma
- Author
-
Groen, Emma Josephine, Wesseling, Jelle, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
246. Invasive Carcinoma with Signet Ring Cell Differentiation
- Author
-
Ellis, Ian, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
247. HER2 in Breast Cancer
- Author
-
Annaratone, Laura, Sarotto, Ivana, Marchiò, Caterina, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
248. Hormone Receptors in Breast Cancer
- Author
-
Shaaban, Abeer M., Speirs, Valerie, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
249. Invasive Carcinoma with Neuroendocrine Differentiation
- Author
-
Chmielik, Ewa, van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
250. Intraductal Papilloma
- Author
-
Ryska, Ales, Torgersen, Folakemi A., van Krieken, J. H. J. M., Series Editor, Sapino, Anna, editor, and Kulka, Janina, editor
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.